NCT02012998View on ClinicalTrials.gov

Study of the Immunogenicity and Safety of a Challenge Dose of HBVAXPRO in Healthy Children Vaccinated 10 Years Ago With 3 Doses of HEXAVAC or INFANRIX HEXA

PHASE3CompletedINTERVENTIONAL
Enrollment

751

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Virus DiseasesHepatitis B
Interventions
BIOLOGICAL

HBVAXPRO 5µg

0.5mL intramuscular injection

Trial Locations (10)

Unknown

Sanofi Pasteur MSD Investigational Site 004, Bologna

Sanofi Pasteur MSD Investigational Site 009, Cagliari

Sanofi Pasteur MSD Investigational Site 005, Capannori

Sanofi Pasteur MSD Investigational Site 003, Chiavari

Sanofi Pasteur MSD Investigational Site 002, Latisana

Sanofi Pasteur MSD Investigational Site 008, Massafra

Sanofi Pasteur MSD Investigational Site 006, Nocera Inferiore

Sanofi Pasteur MSD Investigational Site 010, Ragusa

Sanofi Pasteur MSD Investigational Site 007, Salerno

Sanofi Pasteur MSD Investigational Site 001, Sassari

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT02012998 - Study of the Immunogenicity and Safety of a Challenge Dose of HBVAXPRO in Healthy Children Vaccinated 10 Years Ago With 3 Doses of HEXAVAC or INFANRIX HEXA | Biotech Hunter | Biotech Hunter